Information Provided By:
Fly News Breaks for January 2, 2018
HAE
Jan 2, 2018 | 07:25 EDT
As previously reported, Morgan Stanley analyst David Lewis upgraded Haemonetics to Overweight from Equal Weight, as he contends that the yield opportunity for the company's next generation plasma apheresis system, the NexSys, is not being fully appreciated. Visibility on the company's transformation has improved, added Lewis, who raised his price target on the stock to $74 from $51.
News For HAE From the Last 2 Days
There are no results for your query HAE